Early ctDNA Changes Predict Outcomes in Head and Neck Cancer Patients Under Re-Radiotherapy
Author Information
Author(s): Florian Janke, Florian Stritzke, Katharina Dvornikovich, Henrik Franke, Arlou Kristina Angeles, Anja Lisa Riediger, Simon Ogrodnik, Sabrina Gerhardt, Sebastian Regnery, Philipp Schröter, Lukas Bauer, Katharina Weusthof, Magdalena Görtz, Semi Harrabi, Klaus Herfarth, Christian Neelsen, Daniel Paech, Heinz‐Peter Schlemmer, Amir Abdollahi, Sebastian Adeberg, Jürgen Debus, Holger Sültmann, Thomas Held
Primary Institution: German Cancer Research Center (DKFZ) Heidelberg
Hypothesis
Can circulating tumor DNA (ctDNA) levels predict disease outcomes in head and neck cancer patients undergoing re-radiotherapy?
Conclusion
Quantifying ctDNA during re-radiotherapy may help in monitoring disease and personalizing treatment.
Supporting Evidence
- ctDNA levels after 5 and 10 radiation fractions correlated with short progression-free survival.
- ctDNA positivity was detected in 50% of patients.
- Dynamic ctDNA tracking reflected treatment response and imminent disease progression.
Takeaway
Doctors can check for tiny bits of cancer DNA in the blood to see how well treatment is working for patients with head and neck cancer.
Methodology
The study analyzed ctDNA in plasma samples from patients at multiple time points during re-radiotherapy.
Potential Biases
Potential biases due to the heterogeneous pre-treatments and salvage therapies administered.
Limitations
The study had a small sample size and was retrospective in nature.
Participant Demographics
Median age was 59 years, with 68.8% males and 56% current or former smokers.
Statistical Information
P-Value
p=0.006
Confidence Interval
95% CI = 1.43–26.64
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website